Immune cell status, cardiorespiratory fitness and body composition among breast cancer survivors and healthy women: a cross sectional study

Autor: Ainhoa Arana Echarri, Lauren Struszczak, Mark Beresford, John P. Campbell, Robert H. Jones, Dylan Thompson, James E. Turner

Publikováno v: Frontiers in Physiology, Vol 14 (2023)

Methods: We examined whether immune cell profiles differ between healthy women (n = 38) and breast cancer survivors (n = 27) within 2 years of treatment, and whether any group-differences were influenced by age, cytomegalovirus infection, cardiorespi

Externí odkaz: https://doaj.org/article/9e2ef7a3341043debd7f5288d414dd65

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Autor: Sacha J Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Sian Morgan, Magdalena Meissner, Catherine Bale, Pavel Bezecny, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C de Bruin, Gaia Schiavon, Andrew Foxley, Robert H Jones

Publikováno v: Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4

BACKGROUND: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The ben

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8b7c1cc7c7d91a6ed98ec5f578778f
https://doi.org/10.1016/s1470-2045(22)00284-4

Abstract P1-04-10: Breast cancer survivors exhibit an accumulation of CD4+ central memory T cells, a fall in CD8+ naïve T cells and higher activation of CD4+/CD8+ memory T cells in blood, which is positively correlated with age and fat mass index

Autor: Ainhoa Arana Echarri, Lauren Struszczak, Mark Beresford, John P Campbell, Robert H Jones, Rachel Butler, Dylan Thompson, James E Turner

Publikováno v: Cancer Research. 82:P1-04

Introduction: T cells are important for tumour control and surveillance, but it is not well known how breast cancer treatment impacts their characteristics in blood. Methods: Healthy women (n=38, age 45 ± 11 y), breast cancer survivors (n=27, age 56

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e542118d9d1f677f8477aeac88bedec
https://doi.org/10.1158/1538-7445.sabcs21-p1-04-10

Machine Learning for Stock Selection

Autor: Keywan Rasekhschaffe, Robert H. Jones

Publikováno v: Financial Analysts Journal. 75:70-88

Machine learning is an increasingly important and controversial topic in quantitative finance. A lively debate persists as to whether machine learning techniques can be practical investment tools. Although machine learning algorithms can uncover subt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::559c317fc82768512641fd4ddfc9845c
https://doi.org/10.1080/0015198x.2019.1596678

Robert H. Jones, MD (Born 1940)

Autor: Robert H, Jones

Publikováno v: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 28(2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f544d9d1fccfb15d59f841550dfd2db0
https://pubmed.ncbi.nlm.nih.gov/33655445